• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

About DIA

By DIA
Article

Develop. Innovate. Advance. DIA is the only global organization dedicated to bringing health care product development professionals together in a neutral environment to improve health and well-being throughout the world.

See more at: http://www.diaglobal.org/en/about-us#sthash.uT0zazfD.dpuf

Recent Videos
Related Content
Stock.adobe.com

Lilly Announces $1 Billion Expansion to Ireland Facilities

Mike Hollan
September 13th 2024
Article

To improved facilities will produce ingredients used in Alzheimer’s medications.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

Stock.adobe.com

CVS Pharmacies to Offer Birth Control Prescribing Services in Massachusetts

Mike Hollan
September 13th 2024
Article

These services will help alleviate the impact of contraceptive deserts in the state.

Empty Shelves, Urgent Solutions

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs
August 5th 2024
Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

FDA Approves Tremfya for Moderately to Severely Active Ulcerative Colitis

FDA Approves Tremfya for Moderately to Severely Active Ulcerative Colitis

Don Tracy, Associate Editor
September 12th 2024
Article

Tremfya is the first and only fully-human, dual-acting monoclonal antibody targeting IL-23 and CD64 to be approved for the treatment of moderately to severely active ulcerative colitis.

Pharma Pulse 9/12/24: Enhancing Biologics Development, Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000 & more

Pharma Pulse 9/12/24: Enhancing Biologics Development, Study Finds Cap on Out-of-Pocket Costs Saves Cancer Patients $7,000 & more

Miranda Schmalfuhs
September 12th 2024
Article

The latest news for pharma industry insiders.